LinkedIn
icn_podcast Podcasts
View All Upcoming Courses
Specialty
Course Type
Search
Login
Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology Endocrinology General Ophthalmology Glaucoma Neuro-Ophthalmology Oculoplastics Optometry Retina Women's Health View All Courses
Course Type
Evaluation Supplement Multimedia Webinar Podcast In-Person Multi-part Collection
Search
Login
Menu

Then, Now, and Tomorrow: Evolving the Management of Diabetic Retinopathy and the Role of the Optometrist

By: Eric Nudleman, MD; Nathan Steinle, MD; John D. Pitcher III, MD; and Ehsan Rahimy, MD

Begin Course

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

Diabetic retinopathy (DR) is the most common ocular complication of diabetes, responsible for more than 10,000 new cases of blindness yearly in the United States. This activity focuses on information for optometrists, as their role is crucial in educating patients with diabetes about the potential ocular complications of their systemic disorder and the benefits of diabetic eye exams and early treatment.

Expiration Date: Sunday, May 8, 2022
Release Date: June 15, 2019

Sponsored by an educational grant from Regeneron Pharmaceuticals and Carl Zeiss Meditec.

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Discuss the increasing prevalence of diabetes and diabetic retinopathy.
  • Identify which patients need to be screened earlier based on their disease state.
  • Explain to patients the need for early referral to retina specialists.
  • Summarize how diabetic eye disease may affect patients with visually significant cataract and initiate appropriate treatment for these patients.
  • Discuss how imaging devices may be able to provide earlier diagnosis of disease or disease progression.

Accreditation and Designation Statement

Evolve is an approved COPE Administrator.

This course is COPE approved for 1.0 hours of CE Credit for Optometrists

COPE Course ID: 62633-PS

COPE Event ID: 117503

Faculty and Disclosures

Eric Nudleman, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan plc., and Regeneron Pharmaceuticals.

John D. Pitcher III, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan plc., Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/ Research Support: Alcon. Speakers Bureau: Genentech and Regeneron Pharmaceuticals.

Ehsan Rahimy, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, plc, Genentech, Google, and Regeneron Pharmaceuticals. Speakers Bureau: Regeneron Pharmaceuticals.

Nathan Steinle, MD and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Carl Zeiss Meditec, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant Research Support: Carl Zeiss Meditec, Genentech, and Regeneron Pharmaceuticals. Speakers Bureau: Alimera Sciences, Genentech, Notal Vision, Novartis, and Regeneron Pharmaceuticals, Inc. Stock Shareholder: Vertex Surgical.

Editorial Support Disclosures
Erin K. Fletcher, MIT, director of compliance and education; Susan Gallagher-Pecha, director of client services and project management; Cassandra Richards, director of education development, Evolve; and Michelle Dalton, writer, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan.

 

Disclaimer

Off-Label Statement
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Modern Optometry, Regeneron Pharmaceuticals, or Carl Zeiss Meditec.

Begin Course